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INTRODUCTION

The Centers for Disease Control has proclaimed opioid addiction a
national epidemic.1 According to new research, one in five pregnant
women in the United States take some form of opioid during pregnancy,
and one in twenty are addicted to opioid medications.2 In response, the
government has increased their attempts to regulate pregnant women’s
conduct in order to protect the health of unborn children.3 Opioid
dependent mothers often find themselves subject to being reported to Child
Protective Services (“CPS”) by doctors and hospital staff for ingesting
drugs while pregnant.4
Individuals in substance abuse treatment, including pregnant mothers
receiving opioid replacement therapy, are protected from discrimination
under the Americans with Disabilities Act (“ADA”).5 However, mothers
who are prescribed opioid replacement medication as part of a substance
abuse treatment program are often reported in the same way, and to the
same authorities as mothers who are taking illicit opioids.6 I argue that not
only is there a strong constitutional argument against the practice of
reporting mothers receiving Medication Assisted Therapy (“MAT”) to
social services, but also the way the federal statute is currently written and
applied constitutes illegal discrimination against a group of people
classified as disabled under various federal statutes.
Moreover, inconsistent reporting practices, which vary not only from
state to state, but also from county to county, and hospital to hospital—
create a confusing situation for pregnant mothers receiving opioid

1. CTR. FOR DISEASE CONTROL & PREVENTION, Understanding the Epidemic, https://
www.cdc.gov/drugoverdose/epidemic/index.html (last visited May 1, 2018) [http://perma.
cc/9CU5-E92Z]; see also NBC NEWS, Pregnant on Opiates: When Following Doctors’
Orders Breaks the Law, (May 9, 2014, 1:42 AM), https://www.nbcnews.com/news/usnews/pregnant-opiates-when-following-doctors-orders-breaks-law-n100781 [https://perma.
cc/5F6P-YNTU].
2. Rishi J. Desai et al., Increase in Prescription Opioid Use During Pregnancy Among
Medicaid-Enrolled Women, 123 OBSTETRICS & GYNECOLOGY 997, 1002 (2014); see also
Rachel Blustain, Medical Consensus or Child Abuse? Moms on Methadone Caught in the
Middle, THE DAILY BEAST (Sept. 2012 4:45 AM), https://www.thedailybeast.com/medicalconsensus-or-child-abuse-moms-on-methadone-caught-in-the-middle [https://perma.cc/PP
M5-ZEGE].
3. Brian Bornstein, Pregnancy, Drug Testing, and the Fourth Amendment: Legal and
Behavioral Implications, 188 FAC. PUB., DEP’T PSYCHOL. 220, 220 (2003), http://digital
commons.unl.edu/psychfacpub/188 [http://perma.cc/Q27U-YYJC].
4. Rebecca Stone, Pregnant Women and Substance Use: Fear, Stigma, and Barriers to
Care, 3 HEALTH JUST. (Dec. 2015), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC51
51516/ [http://perma.cc/ER3D-KLKM].
5. 42 U.S.C § 12210 (2008); see also U.S. DEPT. HEALTH AND HUM. SERVICES, Know
Your Rights: Rights for Individuals on Medication-Assisted Treatment, (2009), http://at
forum.com/documents/Know_Your_Rights_Brochure_0110.pdf
[https://perma.cc/SH5NK2PL].
6. See Blustain, supra note 2.
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replacement therapy.7 Federal law,8 including the newly passed SUPPORT
for Patients and Communities Act (“SUPPORT Act”), which was signed
into law on October 24, 2018, provides little guidance to the states and
continues to make funding contingent on regressive reporting practices.9
This issue is further compounded by the fact that the basis for reporting, the
presence of neonatal abstinence syndrome (“NAS”) in the newborn, fails to
distinguish between mothers who are legally prescribed opioids as part of a
treatment program and those who are taking illicit drugs.10
This note makes a plea to lawmakers to address the issue statutorily—
by explicitly defining and creating clear categories of NAS that are
screened using readily available, inexpensive, and reliable methods.
A. THE HISTORY OF MEDICATION ASSISTED THERAPY
Opioid dependence is the fastest growing substance use problem in the
United States, and one of the most common reasons for seeking addiction
treatment worldwide.11 MAT providers utilize opioid analogs in
combination with counseling and behavioral therapies in order to stabilize
and improve patients’ lives.12 The only two drugs federally approved for
use as replacement therapies for opioid dependence in the United States are
methadone and buprenorphine, both of which have been studied
extensively and deemed to be safe.13 In the United States, methadone has
been used for more than five decades, and is dispensed only through
federally approved opioid treatment programs.14 In 2002, the Food and
7. Leticia Miranda et al., How States Handle Drug Use During Pregnancy, PROPUBLICA
(Sept. 30, 2015), https://projects.propublica.org/graphics/maternity-drug-policies-by-state
[http://perma.cc/PZ23-UE9W].
8. See Keeping Children and Families Safe Act of 2003, Pub. L. No. 108-36; see also
The Comprehensive Addiction and Recovery Act S. 524 114th Cong. (2015-2016); see also
SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. (2017-2018).
9. SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. (2017-2018) Pub.
L. No. 115-271 (enacted Oct. 24, 2018).
10. See Lauren Jansson et al., The Opioid Exposed Newborn: Assessment and
Pharmacologic Management, 5 J. OPIOID MGMT. 47–55 (2009) (discussing the various
differential scoring tools commonly used by medical staff to diagnosis NAS. These scoring
tools require medical professionals to observe and rank the infant on different categories
according to the severity of their symptoms. This form of diagnosis does not distinguish
between the substances causing the NAS symptoms); see also NBC NEWS, supra note 1.
11. Gavin Bart, Maintenance Medication for Opiate Addiction: The Foundation of
Recovery, 31 J. ADDICTION DIS. 207, 225 (2012); see also CTR. FOR DISEASE CONTROL &
PREVENTION, Understanding the Epidemic, https://www.cdc.gov/drugoverdose/epidem
ic/index.html (last visited May 1, 2018) [http://perma.cc/9CU5-E92Z].
12. SUBSTANCE ABUSE & MENTAL HEALTH SERVICES ADMIN., Medication and
Counseling Treatment, https://www.samhsa.gov/medication-assisted-treatment/treatment
(last visited May 6, 2018) [https;//perma.cc/D8MC-MXRE].
13. PROVIDERS CLINICAL SUPPORT SYS., Pregnancy: Methadone and Buprenorphine
http://pcssnow.org/wp-content/uploads/2015/10/WAGBrochure-Opioid-Pregnancy_Final.
pdf (last visited May 13, 2018) [https://perma.cc/NDX4-9CYP].
14. SUBSTANCE ABUSE & MENTAL HEALTH SERVICES ADMIN., Report to Congress on the
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Drug Administration (“FDA”) approved buprenorphine for the treatment of
opioid dependence, however, physicians must obtain specialized training to
prescribe it.15 Some of these trained physicians are in private office-based
practices, while others are affiliated with substance abuse treatment
facilities.16
MAT has a proven track record as the most effective treatment for
opioid dependent individuals.17 Patients have substantially lower rates of
dropout than other forms of addiction treatment, and methadone
maintenance (“MM”) treatment is associated with large decreases in
criminal activity, and a reduction in HIV and Hepatitis C transmission.18
Unfortunately, many communities and social service agencies view MAT
providers and their patients with antipathy or disdain.19 Often, they
misunderstand opiate agonist therapy and consider MAT providers to be
little more than legalized drug dealers. Consequently, many communities
and social service agencies want nothing to do with the providers or their
patients.20
B. MOTHERS ON MEDICATION ASSISTED THERAPY
The misuse of opioids during pregnancy significantly increases rates of
preterm birth, spontaneous abortion, and infant mortality.21 Opioid
dependence during pregnancy results in a six-fold increase in obstetric
complications and a seventy-four-fold increase in sudden infant death
syndrome.22 In pregnancy, MAT serves to stabilize the uterine
environment, protecting the fetus from the stress of repeated withdrawal.23
MAT has been considered the gold standard of care for mothers
diagnosed with opioid use disorder for decades.24 Infant mortality rates

Nation’s Substance Abuse and Mental Health Workforce Issues, (Jan. 24, 2013),
https://store.samhsa.gov/shin/content/PEP13-RTC-BHWORK/PEP13-RTC-BHWORK.pdf
[http://perma.cc/4MLZ-XC4L].
15. SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN., https://www.samhsa.
gov/medication-assisted-treatment/training-resources/buprenorphine-physician-training (last
visited Dec. 15, 2019) [https://perma.cc/BN4J-QZR4].
16. Id.
17. Bart, supra note 11.
18. Id.
19. Jeff Deeney, A Methadone Clinic? Not in My Neighborhood!, SUBSTANCE.COM
https://www.substance.com/a-methadone-clinic-not-in-my-neighborhood/ (last visited Apr.
18 2015) [https://perma.cc/8GGH-2LHE].
20. Id.
21. Eliza M. Park et al., Evaluation and Management of Opioid Dependence in
Pregnancy, 53 PSYCHOSOMATICS 424 (2012).
22. O. Fajemirokun-Odudeyi et al., Pregnancy Outcome in Women who use Opiates, 126
EUR. J. OBSTETRICS, GYNECOLOGY, & REPROD. BIOLOGY 170 (2006).
23. Margaret A. Jarvis & Sidney H. Schnoll, Methadone Treatment During Pregnancy,
26 J. PSYCHOACTIVE DRUGS 155 (1994).
24. Stone, supra note 4.
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among mothers receiving MAT are higher than rates among women who
have not used any substances during pregnancy.25 However, when
compared with outcomes of substance-using women who are not in
treatment, it is clear that MAT lowers infant mortality rates and promotes
fetal stability.26 Despite the controversy associated with MAT, it has been
proven to be the most effective treatment for opioid dependent mothers
who have been unreceptive or unsuccessful with abstinence-based
treatment approaches.27 Studies have shown that abstinence without opioid
assisted therapy during pregnancy has only about a 1-4% success or
compliance rate.28 One study of abstinence based treatment showed that out
of 101 pregnant mothers who were opioid dependent, only 42 completed
withdraw, and out of those, only 1 tested free from opioids at delivery.29
Infants prenatally exposed to opioids in utero often become passively
addicted.30 NAS manifests 24-72 hours after birth because the infant is
abruptly cut off from narcotics used by the mother during pregnancy.31
Between 55% and 94% of infants born to opioid dependent women show
signs of NAS.32 The symptoms include: irritability, hyper-reflexia,
hyperactivity, abnormal cry, diarrhea, fever, vomiting, respiratory distress,
tachypnea, convulsions or seizures, and coma.33 Although the symptoms of
NAS are jarring and upsetting to observe, studies have found that NAS
responds well to both pharmacological and non-pharmacological
treatment.34
After adjustment for social disadvantage, the weight of evidence
suggests that methadone treatment throughout pregnancy does not
generally have significant adverse effects on postnatal development.35
When compared to the developmental outcomes of children exposed to

25. Scott A. Shainker, Opioid Addiction in Pregnancy, 67 OBSTETRICAL &
GYNECOLOGICAL SURV. 817 (2012).
26. Ursula A. Pritham et al., Methadone and buprenorphine treatment during pregnancy:
What are the effects on infants?, 11 NURSING FOR WOMEN’S HEALTH 558 (2007).
27. Pritham et al., supra note 26.
28. Jason Luty et al., Is Opiate Detoxification Unsafe in Pregnancy?, 24 J. SUBSTANCE
ABUSE 363 (2003).
29. Id.
30. Karol Kaltenbach & Loretta Finnegan, Neonatal Abstinence Syndrome,
Pharmacotherapy and Developmental Outcome, 8 NEUROBEHAVIORAL TOXICOLOGY &
TERATOLOGY 353, 353 (1986).
31. Prabhakar Kocherlakota, Neonatal Abstinence Syndrome, 134 PEDIATRICS 547 (Aug.
2014).
32. Walter Kraft, Pharmacologic Management of the Opioid Neonatal Abstinence
Syndrome, 59 PEDIATRIC CLINIC N. AM. 1147 (2012); see also AM. ACAD. OF PEDIATRICS
COMM. ON DRUGS, Neonatal drug withdrawal, 101 PEDIATRICS 1079 (1998).
33. Id.
34. Walter Kraft, Buprenorphine in Neonatal Abstinence Syndrome, 103 CLINICAL
PHARMACOLOGY & THERAPEUTICS, 112, 117 (2018).
35. Kaltenbach & Finnegan, supra note 30.
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illicit opioids during pregnancy, the children of mothers maintained on
MAT have better developmental outcomes.36 Generally the long-term
developmental impact for children prenatally exposed to methadone is
minimal and environmental factors in the home are more predictive of later
social and developmental outcomes.37
A review of the scientific evidence reveals that pregnant mothers on
MAT have better treatment outcomes, receive better prenatal care than
mothers using illicit opioids, and have less risk of pre and post-natal
complications.38 Unfortunately, a lack of education and awareness among
healthcare providers and the general population has created a situation that
punishes opioid dependent mothers for doing what science has proven is
best for them and their children.39
One of the principal hurdles when it comes to pregnant mothers on
MAT is stigma. Patients receiving MAT therapies are viewed with distain
and this prejudice is magnified when the opioid dependent individual is a
pregnant woman.40 Patients are often reluctant to seek or continue
treatment fearing the disapproval of friends, family, and service providers,
or due to fear of unknown medical and developmental consequences for the
fetus.41 Even the healthcare providers in the medical unit where infants
diagnosed with NAS are treated tend to “punish” the mothers.42
“[S]ometimes the medical staff doesn’t want the mother to be with the baby
and will work to make sure they are separated.”43 This form of punitive
removal only serves to harm the infant by depriving intimate contact
between infant and mother during a critical stage of bonding, new evidence
suggest that in order to improve developmental outcomes for the infant and
to curb NAS severity, every effort should be made to keep mother and
child together.44 For the sake of the mother-infant dyad, pregnant mothers

36. Kaltenbach & Finnegan, supra note 30.
37. Diana Kronstadt, Complex Developmental Issues of Prenatal Drug Exposure, 1
FUTURE CHILD. 36 (1991).
38. Id. (these outcomes are only expected when the mother is earnestly following a MAT
program and is not engaging is polysubstance abuse. The use of other harmful substances is
common among mothers on MAT, however, this note only concerns mothers on MAT who
are not using other substances).
39. Mishak Terplan et al., Prenatal Substance Use: Exploring Assumptions of Maternal
Unfitness, LIBERTAS ACADEMIA (2015), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC
4578572/ [https://perma.cc/L95M-3TNH].
40. Perilou Goddard, Changing attitudes towards harm reduction among treatment
professionals: A report from the American Midwest, 14 INT’L J. DRUG POL’Y 257 (2003).
41. William Alto & Alane O’Connor, Management of Women Treated with
Buprenorphine During Pregnancy, 205 AM. J. OBSTETRICS & GYNECOLOGY 302 (2011).
42. Blustain, supra note 2.
43. Id.
44. See generally BEHAV. HEALTH COORDINATING COUNCIL SUBCOMM. ON PRESCRIPTION
DRUG ABUSE, PROTECTING OUR INFANTS ACT: FINAL STRATEGY (2017); see also STEVE
CHRISTIAN, SUBSTANCE-EXPOSED NEWBORNS: NEW FEDERAL LAW RAISES SOME OLD ISSUES,
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on MAT should be met with kindness and understanding—not hostility and
judgment.45

II. THE LEGAL ISSUES
A. MOTHERS ON MEDICATION ASSISTED THERAPY ARE PROTECTED
UNDER THE AMERICANS WITH DISABILITIES ACT.
Currently, the federal law creates a requirement that states have
policies and procedures requiring health care providers to notify CPS of
“infants born and identified as being affected by substance abuse or
withdrawal symptoms resulting from prenatal drug exposure.”46 This
federal law lumps mothers who are receiving physician recommended
MAT therapies into the same group as mothers using illicit drugs.47 Instead
of modifying this federal requirement, the newly approved SUPPORT Act,
continues to require that states report all incidences of NAS.48 The practice
of blindly placing all women who give birth to children diagnosed with
NAS in the same category is untenable and discriminatory.
Federal civil rights laws protect qualified individuals with disabilities
from discrimination in many areas of life.49 People in recovery from drug
addiction, including those in MAT, are protected from discrimination by
the following statues: Americans with Disabilities Act, Rehabilitation Act
of 1973, and the Fair Housing Act.50
Section 12102 of the ADA defines a “disability” as “a physical or
mental impairment that substantially limits one or more of the major life
activities…”51 of a “qualified individual.”52 The legislative history of the
NATIONAL CONFERENCE OF STATE LEGISLATURES: CHILDREN’S POLICY INITIATIVE (Sept.
2004).
45. Terplan et al., supra note 39.
46. Keeping Children and Families Safe Act of 2003, Pub. L. No. 108-36; as amended by
P.L. 111-320 & P.L. 115-271.
47. For the purposes of this Note mothers using illicit opioids and mothers testing
positive for opioid use due to their participation in a MAT program are treated as two
separate groups—wherein mothers in MAT programs are assumed not to be engaging in
illicit drug use. The issue of polysubstance abuse by mothers in MAT is serious and often
pervasive. However, for the purposes of this note it can be assumed that when referring to
mothers on MAT, I am specifically referring to mothers who are successfully abstaining
from all illicit and harmful drugs.
48. SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. (2017-2018) Pub.
L. No. 115-271 (enacted Oct. 24, 2018).
49. U.S. DEPT. HEALTH AND HUM. SERVICES, Know Your Rights: Rights for Individuals
on Medication-Assisted Treatment, (2009), http://atforum.com/documents/Know_Your_Ri
ghts_Brochure_0110.pdf [https://perma.cc/SH5N-K2PL].
50. 42 U.S.C § 12101; 29 U.S.C § 701; 42 U.S.C § 3601.
51. 42 U.S.C. § 12102(1)(A)-(C).
52. 42 U.S.C. § 12102(1); see Haley Johnston, Exploring an Old Act for New Protection:
How Title II of the ADA Protects Pregnant Women Undergoing Methadone Treatment from
State Agency Child Removal 4 INDIANA J. OF L. & SOCIAL EQUALITY 99, 114 (2016)
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ADA supports the inclusion of “drug addiction” as one of the forms of
physical or mental impairment protected under the ADA.53
Additionally, Section 12210(b) of the ADA provides that persons
“participating in a supervised rehabilitation program and no longer
engaging in [illegal drug] use” cannot be excluded as a protected class.54
Illegal use of drugs is defined in section 12210(d) as “. . . the use of drugs,
the possession or distribution of which is unlawful under the Controlled
Substances Act.”55 This definition distinctly does not include the use of a
drug taken under the supervision of a licensed health care professional, or
other uses authorized by the Controlled Substances Act or other provisions
of federal law.56
The ADA protects disabled individuals from both private57 and public
entities.58 Public entities are defined broadly as “any state or local
government; any department, agency, special purpose district, or other
instrumentality of a State or States or local government …”59 States,
counties, cities, CPS, private and public hospitals are all entities subject to
the provisions of the ADA, meaning they cannot discriminate against
protected groups.60 Congress intended the ADA’s provisions to apply
broadly and provide strong protections for individuals with disabilities in
an effort to eliminate discrimination.61 Based on this broad understanding
mothers on MAT should be protected under the ADA.
Several courts have confirmed that MAT patients are indeed included
under the ADA’s provision. In Ocasio v. Klassen, the court ruled that the
United States Postal Service’s policy of refusing to hire people on MAT
was discriminatory.62 This decision led the USPS to change its hiring
practices to conform to the Federal Rehabilitation Act.63 In Perez v. New
York State Division of Human Rights, the court held that a person in MAT
treatment has a protected disability under the New York State Human

(discussing what a “qualified individual” is).
53. S. Rep. No 101-116, at 22 (1989) (discussing the meaning and definition of “physical
or mental impairment.” In their non-exhaustive list of examples what would qualify as an
impairment, the Senate included “drug addiction” and “alcoholism”); see Johnston, supra
note 52.
54. 42 U.S.C. § 12210 (2008).
55. Id.; see also 21 U.S.C. § 801 (2012).
56. See 21 U.S.C. § 801 (2012) (declarations concerning controlled substances).
57. 42 U.S.C. § 12184(a).
58. See 42 U.S.C § 12101(b) (2012).
59. 42 U.S.C. §§ 12131(1) (A)-(B).
60. See Haley Johnston, supra note 51 at 112-115 (discussing the application of the ADA
to mothers on methadone).
61. Johnston, supra note 52 at 113.
62. Ocasio v. Klassen, 73 Civ. 2496 (S.D.N.Y. Nov. 25, 1974).
63. Id.
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Rights Law.64 A number of other courts have recognized MAT patients as
being protected based on their disability.65
It is illegal to discriminate against MAT patients based on their
disability because of their status as a protected group.66 CPS and hospitals
have no more of a right to single out MAT patients and require them to stop
taking their medication than they do to tell a diabetic to stop taking their
insulin.67 Therefore, when hospitals and healthcare workers report mothers
who are participating in MAT programs to CPS they are illegally
discriminating against this protected class of women. Additionally, federal,
state and local governments should be forbidden from instituting
discriminatory policies against mothers on MAT. This institutionalized
discrimination forces mothers into a situation where they must discontinue
MAT, obtain an abortion, or risk losing their child to CPS. This
impermissible practice also perpetuates the notion that women possess the
sole responsibility for the care of their children and if they do not live up to
the standard of what a “good mother” should be they are not only
reprimanded, but they deserve this treatment.68
B. A BRIEF DISCUSSION OF POTENTIAL CONSTITUTIONAL ARGUMENTS
The United States Supreme Court held in Robertson v. California that
criminalizing the status of being a drug addict was unconstitutional and
constituted cruel and unusual punishment.69 Furthermore, in Ferguson v.
City of Charleston, the Supreme Court struck down a South Carolina
hospital’s policy of testing pregnant women for cocaine and turning
positive results over to law enforcement for prosecution.70 However, they
did not conclude that all such policies were unconstitutional.71 Although it
is not necessarily unconstitutional to test pregnant mothers for drugs, it
does require their consent.
Testing pregnant mothers for drugs without consent violates their right
to privacy. Mothers on MAT are often tested without their knowledge or
consent. In some instances, the testing practices of hospitals can implicate
Fourth Amendment search and seizure rights when mothers are not
informed that these test are being performed.72 In Griswold v. Connecticut,
the Supreme Court located a women’s right to privacy in making

64. Perez v. N.Y. St. Div. of Hum. Rts., 70 A.D. 2d. 558 (N.Y.S 2d. May 24, 1979).
65. See e.g., New Directors Treatment Servs. v. City of Redding, 490 F. 3d 293 (3d Cir.
2007); see also MX Grp., Inc. v. City of Covington, 293 F. 3d 326 (6th Cir. 2002).
66. See 42 U.S.C. § 12210 (2008).
67. Jansson et al., supra note 10.
68. See Terplan et al., supra note 39.
69. Robertson v. Cal., 370 U.S. 660, 667 (1962).
70. Ferguson v. City of Charleston, 532 U.S. 67, 85 (2001).
71. Id.
72. Wendy Chavkin et al., Drug-Using Families and Child Protection: Results of a Study
and Implications for Change 54 U. PITT. L. REV. 295 (1992).
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reproductive decisions within the Fourth Amendment right to be secure
from unreasonable searches and seizures.73 Oftentimes women are not
informed of the testing that is taking place while their children are being
assessed for a variety of conditions. For example, in Alabama, a state with
a chemical endangerment law, many hospital consent forms were found to
be lacking any information regarding possible testing procedures or the
consequences of positive tests.74 Situations like this violate the mother’s
rights to be free from unreasonable search and seizure.75 Tolerating this
type of invasion creates a situation where it is routine for hospitals to
violate a mother’s right to be informed about, and to consent to such
testing.76
The federal laws mandating the reporting of children suspected of
suffering from NAS are vague and do not provide adequate notice to
mothers on MAT. The federal law’s failure to exempt, distinguish, or
specifically address the reporting of NAS caused by a mother’s
participation in a MAT program deprives these mothers of sufficient notice
that they may be subject to the same reporting as mothers taking illegal
drugs.77 The federal law does not clearly address mothers on MAT and
whether or not they will be reported as if they were taking illicit drugs. The
Keeping our Children and Families Safe Act only required reporting of
NAS caused by exposure to illegal drugs but did not require testing or
procedures for distinguishing between NAS caused by legally prescribed
drugs.78 The language was slightly changed in 2016 by the Comprehensive
Addiction and Recovery Act (“CARA”), which requires that a report be
made for “infants born and identified as being affected by substance
abuse.”79 It remains unforeseen if the terminological shift has had any
actual effect on mothers in MAT because they were already being reported,
however, it did explicitly broaden the group of individuals that hospitals
are required to report. This updated language has been carried over into the
SUPPORT Act.80

73. Bornstein, supra note 3; citing Griswold v. Connecticut, 381 U.S. 479 (1965).
74. Nina Martin, How Some Alabama Hospitals Quietly Drug Test New Mothers—Without
Their Consent, PROPUBLICA (Sept. 15, 2015) https://www.propublica.org/article/how-somealabama-hospitals-drug-test-new-mothers-without-their-consent [https://perma.cc/6FRZ-UPCU].
75. Id.
76. Id.
77. See Keeping Children and Families Safe Act of 2003, Pub. L. No. 108-36; see also
The Comprehensive Addiction and Recovery Act S. 524 114th Cong. (2015-2016); see also
SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. (2017-2018) Pub. L. No.
115-271 (enacted Oct. 24, 2018).
78. Comprehensive Addiction and Recovery Act of 2016, Pub. L. 114-198.
79. See the Comprehensive Addiction and Recovery Act of 2016, Pub. L. 114-198, §
503(b) amending § 106(b)(2)(B) of the Child Abuse Prevention and Treatment Act 42
U.S.C. 5106a(b)(2)(B).
80. SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. (2017-2018) Pub.
L. No. 115-271 (enacted Oct. 24, 2018).
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Despite the broader language, the choice not to explicitly exempt or
require specific screening procedures to identify mothers on MAT was a
missed opportunity which will continue to disadvantage mothers on MAT.
Mothers on MAT are not abusing a substance but rather are partaking in a
treatment program. Therefore, although, this language expands the category
of women to be reported, it still falls short of notifying mothers on MAT
that they are included in this group. I argue that the application of this
reporting requirement is unconstitutionally vague because it does not
provide clear notice to mothers on MAT that they could be sanctioned
under this reporting requirement.
Additionally, there is precedent to raise an equal protection argument.
Studies have shown that although urine tests of both black and white
women revealed both groups are just as likely to have used illicit
substances, black women were ten times more likely to be reported to the
local authorities.81 This type of testing and reporting disproportionately and
discriminatorily impacts the lives of poor women of color.82 The
demographics of opioid users are rapidly changing as the growing class of
opioid abusers tends to be predominantly middle class white suburban
residents. However, the women who are reported and prosecuted still tend
to be poor women of color.83 Additionally, because of the protections MAT
patients are granted under various federal statutes, it is discriminatory to
single these mothers out and force them into a situation where their only
options are to obtain an abortion, discontinue their medical treatment, or
risk losing their child to CPS.
There are several other valid constitutional concerns that could be
raised in this context; however, to raise them all here would be beyond the
scope of this note.
C. CASE STUDY
A brief search of news articles reveals that there are countless instances
of mothers on MAT being separated from their children for following their
doctor’s orders. Rebecca’s story is just one of many that demonstrates the
complicated and difficult situation that mothers on MAT are placed in.84
“Rebecca’s obstetrician was off duty on the day she went into labor in
2010.”85 This posed an insurmountable problem for Rebecca because she
was taking methadone on doctor’s orders—something her regular

81. Sherry Deren et al., Children of Substance Abusers in New York State, 90 N.Y. ST. J.
MED. 179 (1990); U.S. GEN. ACCT. OFF., Drug-exposed infants: A Generation at Risk,
Report to the Chairman, Committee of Finance, U.S. Senate, (1990); see also Ira J. Chasnoff
et al., The Prevalence of Illicit-drug or Alcohol Use During Pregnancy and Discrepancies
in Mandatory Reporting in Pinellas County, Florida, 322 N. ENG. J. MED. 1202 (1990).
82. See Chasnoff et al., supra note 81.
83. Id.
84. Blustain, supra note 2 (mothers name has been changed to protect her identity).
85. Id.
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obstetrician was well aware of.86 Rebecca was legally prescribed
methadone eight months earlier in an effort to help break her addiction to
the prescription painkiller Vicodin.87 Doctors told her it was the best thing
she could do for the fetus growing inside her.88 Despite the fact that every
major health organization in North America supports the use of methadone
during pregnancy for similarly situated mothers, the hospital staff treated
Rebecca with distain and immediately assumed that Rebecca was abusing
methadone.89
“Between contractions, Rebecca tried frantically to convince the staff
that she was only doing what her doctor had ordered.”90 Doctors and
hospital staff ignored her pleas.91 The surgeon asked, “Do you want an
epidural or do you want painkillers?”92 Rebecca remembers him replying
rhetorically: “You probably want painkillers, because you’re a drug
addict.”93 Despite ridicule from hospital staff, Rebecca’s son “Sam, was
delivered via Caesarean section in good health: [weighing in at] 8 pounds,
1 ounce.”94 Rather than waking up to Sam’s face Rebecca was greeted with
a barrage of question from hospital staff and social workers.95 Rebecca had
no chance, the doctors and hospital staff made up their minds before even
talking to her or doing any research into her situation.96 Investigators from
CPS told Rebecca she would not be allowed to go home with her boyfriend
because he was also on MM.97 “They said she could only keep her baby if a
family member supervised her around the clock.”98 She would not even be
allowed to sit in the same room with Sam alone.99
The case dragged on throughout the first year of Sam’s life, which is
common for mothers in Rebecca’s situation.100 Once family service
agencies are involved, they tend to stay involved.101 Rebecca’s doctors
cautioned her that if she weaned herself from methadone too rapidly, she
could relapse.102 Shortly before Sam’s first birthday, Rebecca’s relatives
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.

Blustain, supra note 2.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
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decided they could no longer manage the burden of supervising her, and a
social worker came and placed her son in a foster home.103
In total disregard of what Rebecca’s doctors advised, the judge
assigned to Rebecca’s case said he wouldn’t close her case until she got off
methadone.104 When she introduced letters from experts testifying that the
federal government recommends MM for opioid-addicted women, she said
the judge told her, “I can make a paper airplane out of these papers and
glide it across the courtroom.”105
After the ordeal was resolved and her child returned to her, Rebecca
said a caseworker who visited her home told her: “Y’all did good. Y’all are
reformed. We actually changed you.”106 Rebecca has a different view of
what happened: “What they did was terrify us, traumatize my son, ruin my
relationship with my family, and leave us in so much debt that we lost our
house. I felt like they’d destroyed my life, even though everything I’d done
since I’d found out I was pregnant was absolutely legal.”107
Cases like this are becoming increasingly more common.108 Maternalhealth and drug treatment advocates report that more patients are being
charged with child abuse for undergoing MAT despite the strong scientific
evidence that MAT is the most effective treatment for pregnant mothers
with opioid addiction.109 In some areas of the country the number of infants
admitted to the NICU for NAS has increased tenfold.110 This statistic is not
surprising considering that between 2000 and 2009 there has been a fivefold increase in reports of pregnant women using opioids and the numbers
have only gotten worse in recent years.111
Compounding the issue is the fact that in the majority of states the
diagnostic tool used to determine NAS fails to distinguish between mothers
in MAT treatment and those taking illicit opioids.112 The enforcement of
the federal rule requiring reporting of NAS is completely arbitrary with
hospitals in the same county having differing policies.113 Moreover,

103. Blustain, supra note 2.
104. Id.
105. Id.
106. Id.
107. Id.
108. Bart, supra note 11.
109. Id.
110. Kocherlakota, supra note 31.
111. M. J. Hayes & M. S. Brown, Epidemic of Prescription Opiate Abuse and Neonatal
Abstinence, 307 JAMA 1974,1975 (2012); see also R. J. Desai et al., Increase in
Prescription Opioid Use During Pregnancy Among Medicaid-Enrolled Women, 123
OBSTETRIC GYNECOLOGY 997 (2014).
112. Maia Szalavitz, How Drug Laws Aimed at Pregnant Women Penalize Their Children,
THE VERGE (Mar. 25 2016) https://www.theverge.com/2016/3/25/11301898/prenatal-drugtesting-custody-laws-child-welfare [https://perma.cc/FFP3-7RZ5].
113. NBC NEWS, supra note 1.
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caseworkers and judges appear to overrule doctors’ orders and even official
child-welfare policies.114 Mothers get caught in the middle because
“[j]udges and caseworkers are practicing medicine without a license, even
against medical advice.”115 This frightening and confusing landscape helps
explain why parents struggling with addiction often choose to hide their
drug problems rather than ask for help.116
D. STATE AND LOCAL POLICY DICTATES TESTING POLICIES
There is currently no national standard of care or protocol for screening
or treating NAS.117 Federal law simply requires the reporting of “infants
born with and identified as being affected by substance abuse or
withdrawal symptoms resulting from prenatal drug exposure.”118 There are
multiple scoring tools used to screen infants to determine the appropriate
course of treatment, however, none of them distinguish the medications
used in MAT from illicit opioids.119
Because of the lack of clear federal regulation, screening procedures,
legal standards, and policies vary widely from state to state.120 Fifteen
states have laws that require healthcare professionals to report pregnant
mothers if drug use is suspected.121 However, only four states have laws
that require hospitals to test infants and mothers for controlled
substances.122 Even among the states that require drug testing the hospitals
are left with the discretion to decide when, how, and who to test.123
Of forty-six states that responded to the Government Accountability
Office’s questionnaire,124 seventeen reported that all notifications of
substance-affected infants are accepted for investigation, regardless of the
circumstances.125 The remaining twenty-nine states reported that they apply
specific criteria to determine if children who present as substance-affected

114. Blustain, supra note 2.
115. Id.
116. Id.
117. See CHRISTIAN, supra note 44.
118. See Keeping Children and Families Safe Act of 2003, Pub. L. No. 108-36; see also
The Comprehensive Addiction and Recovery Act S. 524 114th Cong. (2015-2016); see also
SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. (2017-2018) Pub. L. No.
115-271 (enacted Oct. 24, 2018).
119. See Jansson et al., supra note 10.
120. U.S GOV’T ACCOUNTABILITY OFFICE, GAO 18-196, SUBSTANCE-AFFECTED
INFANTS—ADDITIONAL GUIDANCE WOULD HELP STATES BETTER IMPLEMENT PROTECTIONS
FOR CHILDREN (Jan. 2018) [hereinafter GAO 18-196].
121. Id.
122. Id.
123. CHRISTIAN, supra note 44.
124. GAO 18-196, supra note 120.
125. Id.
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are accepted for investigation by CPS.126 “Examples of the differences
include the following: South Carolina relies on a single positive drug test
result, Florida mandates reporting newborns that are ‘demonstrably
adversely affected’ by prenatal drug exposure, and in Texas, an infant must
be “addicted” to an illegal substance at birth.”127 The federal law allows for
too much inconsistency and places pregnant mothers on MAT in the
precarious situation of not knowing who to trust or what standard they will
be held to.128 This creates poor outcomes for both the mother and the
developing fetus.
States also vary widely in the severity and type of enforcement
mechanisms they choose to implement. For example, in 2014, Tennessee
adopted a statute that specifically made it a crime to use drugs while
pregnant—fortunately the state has since let the statute expire.129
Additionally, high courts in Alabama and South Carolina have interpreted
existing child endangerment statutes to allow for prosecution of drug
dependent pregnant mothers.130 Eighteen states have chosen to impose civil
liability for child abuse due to substance abuse during pregnancy and three
states allow involuntary commitment of mothers found to be using drugs.131
Wisconsin civil commitment laws are especially regressive and actually
allows for a pregnant mother to be detained against her will for the duration
of the pregnancy and provides the fetus with a court-appointed attorney.132
The wide array of sanctions only serves to further alienate pregnant
mothers from the medical and social welfare systems.
The ‘Protecting Our Infants Act: Final Strategy’ issued by the
Department of Health and Human Services (“HHS”) found that it is
necessary to distinguish NAS caused by non-opioid drugs and NAS caused
by opioid drugs to better evaluate postnatal care protocol.133 The report
recommended a terminological shift that would classify NAS caused by
opioids as Neonatal Opioid Withdraw Syndrome (“NOWS”).134 Some
states have attempted to take steps to create a more equitable situation for
mothers on MAT while still working within federal reporting guidelines.
States like Massachusetts and Oregon have followed GAO and HHS
recommendations by directing their efforts towards developing new
screening processes, procedures and policies to identify NAS and

126. GAO 18-196, supra note 120.
127. CHRISTIAN, supra note 44.
128. Id.
129. Miranda, supra note 7.
130. Id.
131. Id.
132. Id.
133. BEHAV. HEALTH COORDINATING COUNCIL SUBCOMM. ON PRESCRIPTION DRUG ABUSE,
PROTECTING OUR INFANTS ACT: FINAL STRATEGY (2017).
134. Id.
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NOWS.135 Massachusetts has developed policies that recognize the
importance of distinguishing NAS caused from exposure to drugs such as:
benzodiazepines, alcohol, cigarettes, hypnotics, cocaine, and stimulants and
NAS that is directly caused by prenatal-exposure to opioids.136 This is a
step in the right direction because it allows for better treatment protocols to
be developed that specifically cater to infants experiencing NAS because of
their mother’s opioids use during pregnancy.137 Although this is a useful
distinction, it can be taken further. The technology is readily available to
distinguish methadone and buprenorphine, the two commonly prescribed
opioid replacement therapy drugs, from other opioids of abuse.138
One very common and troubling occurrence that makes this screening
process and distinction difficult is polysubstance abuse.139 Even mothers
properly maintained on MAT may still struggle with other substances,
including, cigarettes and alcohol. Two substance that are well known to
cause severe birth defects and developmental issues in the fetus. In
instances of polysubstance abuse standard reporting protocols should be
instituted regardless of the mother’s participation in a MAT program.
“[I]n Massachusetts, CPS can “screen out” referrals of mothers if the
only substance affecting the infants was used by the mothers as prescribed
by their physician.”140 When CPS in Massachusetts is notified by the
hospital about an infant, the screener gathers information from the caller
and consults with a supervisor to determine whether the referral should be
accepted for investigation or screened out.141 If the mother is on methadone
and in a treatment program, CPS can verify with medical or other qualified
providers that the mother used the drug legally and as prescribed.142 The
screener can then determine whether the investigation should be ended or if
more information is necessary.143
Oregon has also taken action to develop protocols and procedures that
identify mothers with opioid use disorder (“OUD”).144 Oregon officials
135. See generally OR. HEALTH AUTHORITY, OR. PREGNANCY AND OPIOIDS WORKGROUP
RECOMMENDATIONS, OHA 8280 (2017-2018) see also COMMONWEALTH OF MASS. ,
INTERAGENCY TASK FORCE ON NEWBORNS WITH NEONATAL ABSTINENCE SYNDROME, STATE
PLAN FOR THE COORDINATION OF CARE AND SERVICES FOR NEWBORNS WITH NEONATAL
ABSTINENCE SYNDROME AND SUBSTANCE-EXPOSED NEWBORNS (Mar. 17, 2017).
136. See generally COMMONWEALTH OF MASS., supra note 135.
137. BEHAVIORAL HEALTH COORDINATING COUNCIL SUBCOMM. ON PRESCRIPTION DRUG
ABUSE, PROTECTING OUR INFANTS ACT: FINAL STRATEGY (2017).
138. HEALTH QUALITY ONTARIO, OPTIMUM METHADONE COMPLIANCE TESTING: AN
EVIDENCE BASED ANALYSIS, 6 ONTARIO HEALTH TECH. ASSESSMENT SERIES 1 (2006).
139. GAO 18-196, supra note 120, at 16.
140. Id.
141. Id.
142. Id.
143. Id.
144. See generally OR. HEALTH AUTHORITY, OREGON PREGNANCY AND OPIOIDS
WORKGROUP RECOMMENDATIONS, OHA 8280 (2017-2018).
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developed the Oregon Pregnancy and Opioids Workgroup (“OPOW”) in
recognition of the need for a comprehensive approach to optimizing health
outcomes for mothers with OUD and their infants.145 The OPOW has
focused much of their effort on developing strategies to identify pregnant
mothers with OUD.146 This includes attempts at fact finding before
delivery.147 Oregon uses various questionnaires and databases to determine
if mothers are enrolled in a MAT program in addition to other institutional
safeguards that help coordinate the flow of information between healthcare
providers.148
Both the Oregon and Massachusetts programs specifically attempt to
identify mothers who are using opioids and whose children are likely to be
born suffering from NAS. However, they are doing so within a federal
framework that stifles them and essentially compels them to report all
incidences of NAS. The lack of federal guidance and the variation between
state policies is damaging to pregnant mothers with OUD because it leaves
them in fear of persecution which often causes them to avoid contact with
healthcare providers.
The situation is further compounded by the variation at the county
level. Not only do the policies and laws regarding testing and reporting of
prenatally drug-exposed children vary by state, but there is also
inconsistency at the local level.149 “You can have counties right next to
each other where one would not bat an eye at a baby diagnosed with NAS
[and experiencing withdrawal from MAT] and would allow parents and
doctors to proceed as they wish. In the next county, the baby may be kept
from going home from the hospital with the mother.”150 Many counties
around the country consider NAS grounds for reporting cases to child
welfare services regardless of whether the NAS symptoms are the result of
MAT drugs or heroin.151 Depending on where the mother resides, she
might be subject to reporting, mandatory drug treatment, or even prison.152
This is considered a perfectly acceptable practice because the federal law
does not require further blood testing or for hospitals to distinguish
between legally prescribed medications and illicit drugs.
The laws currently implemented that dictate the testing and reporting of
prenatal drug exposure using NAS scoring criteria discriminate against and
punish pregnant mothers undergoing MAT. There are no cases directly on
point but the courts have addressed similar questions in dicta. For example,

145.
146.
147.
148.
149.
150.
151.
152.

OR. HEALTH AUTHORITY, supra note 144.
Id.
Id.
Id.
NBC NEWS, supra note 1.
Id.
Id.
Id.
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in N.J. Division of Child Protection and Permanency v. Y.N., a New Jersey
judge stated, “[w]here there is evidence of actual impairment, it is
immaterial whether the drugs were from a legal or illicit source.”153 I argue
that this reasoning is wrong and unjustly discriminates against a protected
class of people.154 Conversely, in Doe v. Roe, a New York plaintiff
successfully challenged denial of employment because of a drug test that
could not distinguish between an opioid and a poppy seed bagel.155 The
court ruled that the employer violated New York State’s Human Rights
Law.156 I would argue that, in the context of pregnant mothers on MAT, the
protected interest is even greater. Testing procedures for NAS should
differentiate between illicit drugs and legally prescribed MAT.
Additionally, after a drug test indicates the presence of medications used in
MAT, a follow-up should be done with the mother and her prenatal health
care providers to verify participation in a MAT program. Policies and
screening procedure like those developed by special taskforces in
Massachusetts and Oregon are a step in the right direction, however, they
can be taken further. The current testing and reporting procedures punish
mothers for taking the advice of their doctors and of every major medical
organization in this country.157 I argue that it is unlawful discrimination and
a violation of patient’s rights to punish them for following the
recommended course of care.

III. CHANGING THE LEGAL LANDSCAPE
A. IS THERE POSSIBLE HOPE FOR A SOLUTION IN THE SUPPORT FOR
PATIENTS AND COMMUNITIES ACT?
According to the SUPPORT for Patients and Communities Act
(“SUPPORT Act”) which was recently signed into law October 24th, 2018,
reporting of mothers giving birth to children displaying symptoms of NAS
is still required and encouraged.158 The bill garnered overwhelming support
from both Republicans and Democrats alike. After passing in the House
with a 396-14 margin, the bill moved to the Senate where it received an

153. N.J. Div. of Child Prot. & Permanency v. Y.N., 220 N.J. 165 (2014).
154. 42 U.S.C. § 12102 (2008).42 U.S.C. § 12102; see also supra sections II (A)&(B)
(discussing the legality of discriminating against individuals in substance abuse treatment—
specifically pregnant mothers on MAT).
155. Doe v. Roe, 539 N.Y.S. 2d 876 (N.Y. Sup. Ct. 1989) affirmed in Doe v. Roe, 160
A.D. 2d 255 (App. Div. 1st Dept. 1990).
156. Id.
157. AM. CONG. OF OBSTETRICIANS & GYNECOLOGIST, Tool Kit on State Legislation:
Pregnant Women & Prescription Drug Abuse, Dependence and Addiction, https://www.
acog.org/-/media/Departments/Government-Relations-and-Outreach/NASToolkit.pdf (last
visited May 20, 2018).[https://perma.cc/BYA5-JM63].
158. SUPPORT Act, H.R. 6 115th Cong. Subtitle G § 7065 (d)(ii)(I).
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almost unanimous vote of 98-1.159 The SUPPORT Act is actually a
conglomeration of smaller pieces of legislation that concern the current
opioid crisis. Critics of the legislation say that the SUPPORT Act does not
go far enough to ensure funding for resources and treatment in the future.160
The SUPORT ACT is the largest piece of legislation to be enacted
specifically addressing opioids and contains a multitude of provisions that
concern mothers and children affected by the opioid crisis.161 Specifically
relevant to the discussion at hand are a variety of provisions in Title VII.
Subtitle G-Protecting Pregnant Woman and Infants.162
At this point the bill itself does nothing to explicitly establish a more
equitable standard for determining NAS in newborns. According to section
7065 (a)(7)(C)(iii), in order to receive certain funding and block grants, the
state must ensure the federal government that they will comply with the
reporting requirements instituted by the Child Abuse Prevention and
Treatment Act (“CAPTA”), which fails to specify a standard to differentiate
between NAS caused by opioids prescribed as part of a MAT program, and
NAS resulting from exposure to other substances.163 This essentially leaves
pregnant women on MAT in the same situation as they were.
However, there is some light at the end of the tunnel: Title VII-Subtitle
G-Section-1005 of the bill requires the Secretary of Health and Human
Services to issue guidance to improve the care of infants with NAS and
their families.164 The same Title also authorizes a GAO study of neonatal
abstinence syndrome, something that was approved and completed by the
Obama administration in 2017.165 However, the focus of the 2017 study
was on gaps in Medicaid funding and postnatal care protocols.166 The study
authorized by the SUPPORT Act specifically requires “a report regarding
the implementation of the recommendations in the strategy relating to
prenatal opioid use, including neonatal abstinence syndrome, developed
pursuant to Section 2 of the Protecting Our Infants Act of 2015 . . .”167
Hopefully this study will identify the need for progressive guidance and
159. Bill History Congressional Record, (last visited Nov. 18, 2018) https://www.cong
ress.gov/bill/115th-congress/house-bill/6/all-actions?overview=closed&q=%7B%22roll-cal
l-vote%22%3A%22all%22%7D [https://perma.cc/9GWD-7YXS].
160. Abby Vesolulis, Opioid Bill Shows Congress Can Still Work Together, TIME
MAGAZINE (Oct. 6, 2018) http://time.com/5416380/opioid-bill-congress/ [https://perma.
cc/XE8V-F6ZL].
161. See generally SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong.
(2017-2018) Pub. L. No. 115-271 (enacted Oct. 24, 2018).
162. SUPPORT Act, H.R. 6 115th Cong. Title VII, Subtitle G.
163. SUPPORT Act, H.R. 6, 115th Cong. Title VII, Subtitle G § 7065 (a)(7)(C)(i)(ii).
164. SUPPORT Act, H.R. 6, 115th Cong. Title I § 1005 (a).
165. SUPPORT Act, H.R. 6, 115th Cong. Title I § 1005 (b).
166. U.S. GOV’T ACCOUNTABILITY OFF., GAO 18-32 NEWBORN HEALTH: FEDERAL ACTION
NEEDED TO ADDRESS NEONATAL ABSTINENCE SYNDROME (Oct. 2017) [HEREINAFTER GAO
18-32].
167. Public Law 114–91(Nov 25, 2015).
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regulations at the federal level that recognize the illegality of removing
children from their mothers based on their participation in medically
approved and scientifically proven MAT programs.
One of the more interesting sections of the legislation regarding
mothers on opioid replacement therapy and NAS is section 7065
(a)(C)(i)(IV), which requires that the states monitor the implementation of
plans of safe care with regards to differences between substance use
disorder and medically supervised substance use, including for the
treatment of substance abuse.168 This creates a situation where states must
have a plan that monitors and distinguishes between NAS caused by
medically approved prescription medication, including medication
administered as part of a MAT program, in order to receive funding.
Although, this is a far cry from an explicit requirement that pregnant
mothers in MAT programs be held out as a separate group, it is a positive
indication that states will be required to distinguish between mothers on
MAT, and those taking illicit drugs. This could help lead to a policy change
in the way infants are assessed for NAS.
The SUPPORT Act also explicitly encourages states to “. . . develop
policies, procedures or protocols for the development of evidence-based
and validated screening tools for infants who may be affected by substance
use withdrawal symptoms . . .”169 This provides an opportunity for states to
come into compliance with the ADA by developing a screening process
that distinguishes between withdrawal symptoms precipitated from the use
of illegal drugs and those resulting from the mother’s participation in a
medically approved MAT program. As a protected class of people, mothers
on MAT should not have their children forcibly removed from them simply
for following evidence-based best practices. It is only a slight burden on the
states to require hospitals to switch from using a diagnostic scoring tool
alone, to the use of a diagnostic scoring tool plus a drug screen that
distinguishes between MAT drugs and other substances. It is reassuring
that the SUPPORT Act is encouraging states to develop evidence-based
validated screening tools, and hopefully, this will encourage a departure
from relying solely on diagnostic scoring tools.
Additionally, the SUPPORT Act requires that the recommendations
developed in the report “Protecting Our Infants Act: Final Strategy”, issued
by HHS in 2017 be implemented.170 The Protecting Our Infants Act: Report
to Congress report found that it is necessary to distinguish NAS caused by
non-opioid drugs and NAS caused by opioid drugs to better evaluate

168. SUPPORT Act, H.R. 6, 115th Cong. Title VII, Subtitle G 7065 (a)(C)(i)(IV).
169. SUPPORT Act, H.R. 6, 115th Cong. Title VII, Subtitle G § 7065 (a)(D)(i)(II)(aa).
170. SUPPORT Act, H.R. 6, 115th Cong. Title VII, Subtitle G § 7063 (b)(3).
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postnatal care protocol.171 The report recommended a terminological shift
that would classify NAS caused by opioids as Neonatal Opioid Withdraw
Syndrome (“NOWS”).172
The report suggests that this would lead to better treatment outcomes
for infants. Although this is a step in the right direction, I would argue that
there should also be a delineation between NOWS cause by illicit opioids
use, and NOWS that result because the mother was participating in a MAT
program during pregnancy. The testing technology to distinguish
Methadone and Buprenorphine from other opioids is readily available and
relatively inexpensive.173 Additionally, protocols for reporting mothers in
MAT programs should be tailored to acknowledge their efforts instead of
punishing them for following doctor’s orders. On the whole, the
recommendations in the “Protecting Our Infants Act: Final Strategy” are
mostly positive. However, more could be done to protect mothers on MAT
from having their rights and privileges stripped.
The SUPPORT Act contains other provisions that although not aimed
directly at protecting mothers on MAT, signal a shift in thinking that it is
better to keep mother and child together if at all possible—such as
provisions that make Medicaid funding available for Residential Pediatric
Recovery Centers (“RPRC’s”).174 RPRC’s are essentially recovery centers
that provide comprehensive treatment and counseling and are aimed at
keeping mother and child together after birth.175 However, there are also
provisions that uphold mandatory reporting of mothers whose children
have been identified as experiencing NAS symptoms without requiring a
definitive and distinguishing testing methodology.176 This dichotomy
creates a situation where mothers on MAT are still left without clear or
absolute answers. However, a potential glimmer of hope comes from the
SUPPORT Act’s many research directives, which could have significant
effects for mothers on MAT in the near future. Time will tell if mothers on
MAT will continue to have to live in fear that their child will be taken from
them for following doctor’s orders.

171. THE BEHAVIORAL HEALTH COORDINATING COUNCIL SUBCOMMITTEE ON PRESCRIPTION
DRUG ABUSE, PROTECTING OUR INFANTS ACT: REPORT TO CONGRESS, https://www.samhsa.
gov/sites/default/files/topics/specific_populations/protecting-our-infants-act-report-cong
ress-2017.pdf [https://perma.cc/W7FG-6KZK].
172. Id.
173. HEALTH QUALITY ONTARIO, supra note 138.
174. SUPPORT Act, H.R. 6, 115th Cong. Title 1, § 1007 (b)(pp).
175. SUPPORT Act, H.R. 6, 115th Cong. Title 1, § 1007 (b)(pp).
176. SUPPORT Act, H.R. 6, 115th Cong. Title VII, Subtitle G § 7065 (a)(D)(ii)(I); see
also SUPPORT Act, H.R. 6, 115th Cong. Title VII, Subtitle G § 7065 (a)(D)(iii)(I).
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B. RECOMMENDATION FOR A PROPOSED FEDERAL LAW
The federal law currently discriminates against mothers maintained on
MAT therapies.177 The Keeping Children and Families Safe Act makes
funding for state child welfare services through CAPTA,178 contingent
upon reporting instances of NAS.179 This is a practice that the SUPPORT
Act will continue to mandate. The problem is that the federal law is crafted
in a way that lumps all cases of NAS into one group. This has resulted in a
situation where mothers acting on the best medical advice available are
subject to being reported to child protective services and possibly losing
custody of their children.180
In order to begin to remedy the situation, the federal law should be
amended to include language that distinguishes instances of NAS caused
by prenatal exposure to opioids prescribed to treat OUD, and NAS
resulting from illicit drug use. Alternatively, the statute could be amended
to include an exception for NAS that is the result of a mother’s
participation in a MAT program. That way if a mother presents evidence
that she is enrolled in a MAT program, hospital staff will not be compelled
to report her to authorities, assuming there are no other drugs in her system.
Currently, the instruments used to diagnose NAS do not identify the
substance that is causing the syndrome.181 This is because the federal law is
silent on the methods states are required to use to determine NAS.
Complicating the issue is the fact that the vast majority of states do not use
a urine, blood, or other form of drug test to diagnosis NAS.182 Instead, they
rely on a Diagnostic Scoring Tool.183 This issue could be remedied by
using a drug test to determine the presence or absence of drugs, the type of
drugs, and then requiring a follow-up with the mother about the results. Or,
conversely, if the initial diagnostic scoring tools indicate the infant is
suffering from NAS, then a drug test can be administered to determine the
drugs involved. The technology has been available for decades to
distinguish between the types of medications administered as part of a
MAT program and illicit opioids.184 The tests are inexpensive and could
save mothers and their children tremendous damage and heartache.185
In most cases, mothers maintained on MAT are doing so out of concern
for their child’s welfare. Mothers who come in with documentation or have

177. Jansson et al., supra note 10.
178. 42 U.S.C § 5106(b)(2)(B); see also the Child Abuse Prevention and Treatment Act §
106(b)(2)(B).
179. CHRISTIAN, supra note 44.
180. NBC NEWS, supra note 1.
181. Szalavitz, supra note 112.
182. Id.
183. Id.
184. HEALTH QUALITY ONTARIO, supra note 138.
185. Id.
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given notice to hospital staff and their OBGYN’s should not be subject to
reporting for child abuse, or criminal child endangerment sanctions. Studies
have repeatedly shown that it is in the best interest of the mothers, the
infants, and society to allow mother and child to remain together, except in
the most extreme situations.186 In order to effectively institute a policy that
helps realize that goal the federal law must be amended or replaced.
C. DE-STIGMATIZING THROUGH EDUCATION
Social stigma is a significant part of the problem and must be addressed
in a systematic fashion. A national study completed in 2017 by the
Government Accountability Office (“GAO”) stated that addressing and
educating healthcare professionals about the stigma associated with
pregnant mothers and NAS is extremely important.187 The SUPPORT Act
has made some strides concerning resources and funding for opioid
dependent mothers, however, more has to be done to educate the public and
combat stigma.
Many health professionals and social service providers view MAT
patients with antipathy or distain.188 They view MAT therapy as little more
than legalized drug dealing and consequently want nothing to do with the
treatment provider or its patients.189 This concern is magnified when the
opioid-dependent individual is a pregnant woman.190 This stigma creates a
situation where mothers avoid contact with healthcare professionals out of
fear of being judged and in some cases even jailed or sanctioned.191
Pregnant mothers on MAT are often reluctant to seek or continue their
MAT program, fearing judgment and ridicule, or due to apprehension about
unknown medical and developmental consequences for the fetus.192 Both of
these situations leave the fetus in a precarious and often dangerous
situation.
Because healthcare providers tend to judge mothers on MAT they are
quick to utilize what punitive mechanism they have available. Richard
Wexler, the Director for the National Collation for Child Protection Reform
said, “[w]e don’t have a child welfare system, we have a parent punishment
system.”193 Prejudices about illegal drug users tend to trump rational
consideration about what is best for the children of opioid dependent
mothers.194 Wexler also stated, “[i]f we really believe all the rhetoric about
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putting children’s needs first, we have to put them ahead of everything,
including how we may feel about their mothers.”195 The science has proven
that MAT is the safest and most effective treatment for mothers addicted to
opioids and their fetuses.196 In order to bring policy in line with the science
there must be an effort to educate healthcare professionals and social
service agencies.197
Outside of changing the law, education may be the most powerful and
productive tool available. Studies have shown that educating healthcare
professionals about MAT and other harm reduction treatments can have a
significant effect on the way they view theses treatment modalities and the
patients that receive them.198 It would be immensely beneficial for
healthcare professionals to understand that although the symptoms are the
same for NAS caused by illegal and legal opioid use, the mental state,
preparedness, and health of the mother is not.
Opioid dependence is a notoriously difficult addiction to beat. By
refraining from illicit opioids and working a successful MAT program a
pregnant mother has surmounted immeasurable odds and deserves help and
kindness from medical staff in the maternity ward, not distain, contempt,
and judgment. Additionally, mothers who are using illicit drugs should also
be met with kindness and offered help, not threatened with civil and
criminal sanctions. Although, revising the federal law is an important step
towards correcting the problem, challenging the stigma associated with the
issue is a goal that is achievable now.

IV. CONCLUSION
The current legal landscape concerning mothers on MAT is dangerous.
In order to better protect the rights of mothers receiving MAT therapies and
their children, federal law should be altered to distinguish NAS caused by
illicit drug use, and NAS resulting from prenatal exposure to MAT. The
SUPPORT Act falls short of making this distinction and instead continues
to allow the states to develop their own best practice. This was a missed
opportunity to resolve a serious injustice that violates the statutory
protections mothers on MAT are entitled to. States need a federal statute
that provides guidance on how to best deal with these vulnerable patients.
The use of opioids in the United States is at an all-time high and there is an
epidemic of children being born suffering from NAS. It is imperative that
these children are given the best opportunity for success. Social stigma
paired with discriminatory laws are already putting them at a disadvantage.
In order to mitigate and reverse this situation, the law and the healthcare
system must catch up to the science—the harm is too grave to ignore.
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